Arvisol 150mg

DRUG3 trials

Sponsors

Cannabibs Sp. z o.o., Assistance Publique Hopitaux De Paris, University Hospital Of Clermont-Ferrand

Conditions

Head and Neck CancerIrritable Bowel Syndrome (IBS) type DPatients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

Phase 2

A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting with Symptoms Associated with Irritable Bowel Syndrome with code GSL-01-001

RecruitingCTIS2024-514685-39-00

Cannabibs Sp. z o.o.Irritable Bowel Syndrome (IBS) type D

Start: 2025-02-25Target: 35Updated: 2025-10-06

CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II trial

RecruitingCTIS2024-518455-28-00

Assistance Publique Hopitaux De ParisPatients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

Start: 2024-07-03Target: 210Updated: 2025-04-18

PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial

Not yet recruitingCTIS2024-519637-32-00

University Hospital Of Clermont-FerrandHead and Neck Cancer

Target: 30Updated: 2025-09-16